OrthoPediatrics Q4 prelim revenue beats; forecasts 2026 revenue of $262 mln-$266 mln

Orthopediatrics

12/01/2026 12:15

Overview

Pediatric orthopedics firm's preliminary Q4 revenue beat analyst expectations

Company reported record preliminary full year 2025 revenue growth of 15% yr/yr

Company projects 2026 revenue growth of 11% to 13% and $25 mln adjusted EBITDA

Outlook

OrthoPediatrics projects 2026 revenue between $262 mln and $266 mln

Company expects 2026 adjusted EBITDA of approximately $25 mln

OrthoPediatrics sees specialty bracing as a strategic growth driver

Result Drivers

TRAUMA AND DEFORMITY - Trauma and Deformity and Scoliosis implant businesses drove revenue growth and profitability, per CEO David Bailey

SPECIALTY BRACING - OPSB business seen as a strategic catalyst and capital-efficient driver of revenue and earnings

EUMDR CERTIFICATION - Achieved EUMDR certification for various products, potentially supporting future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$61.30 mln
$59.28 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $23.50, about 28.3% above its January 9 closing price of $18.31

Press Release: ID:nGNX1BkhK5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)